Department of Anesthesiology & Critical Care, Government Institute of Medical Sciences, Gautam Buddha University, Greater Noida, India.
Department of Pharmacology, Government Institute of Medical Sciences, Greater Noida, India.
Curr Drug Saf. 2023;18(2):202-206. doi: 10.2174/1574886317666220513095618.
Occurrence of adverse drug reactions (ADRs) in COVID-19 patients has not been extensively studied.
The present study was conducted to analyze the pattern of suspected ADRs in the COVID-19 Intensive Care Unit (ICU).
In this cross-sectional study, all the individual case study reports of patients admitted to the COVID ICU (August-October 2020) were analyzed for type of ADRs, system involved, suspected drug, onset time, time to revert and management.
Thirty six patients (out of 395 patients admitted) experienced 44 ADRs. Dermatological manifestations were the most frequent ADRs. Remdesivir was the most common drug associated with ADRs. The female gender, polypharmacy (>5 drugs) and presence of comorbidities were the independent risk factors for the occurrence of ADRs.
Use of many of these drugs in COVID-19 is experimental and the literature does not guarantee their safety and efficacy. During these times of uncertainty, the results from the present study reinforce the importance of monitoring patients.
COVID-19 患者的不良反应（ADR）发生情况尚未得到广泛研究。
本研究旨在分析 COVID-19 重症监护病房（ICU）中疑似 ADR 的发生情况。
在这项横断面研究中，对 2020 年 8 月至 10 月入住 COVID ICU 的所有患者的个体病例研究报告进行了分析，以确定 ADR 的类型、涉及的系统、可疑药物、发病时间、恢复时间和处理方法。
36 名（395 名入住患者中的）患者出现 44 种 ADR。皮肤表现是最常见的 ADR。瑞德西韦是与 ADR 最相关的药物。女性、多种药物（>5 种药物）和合并症是发生 ADR 的独立危险因素。
在 COVID-19 期间使用许多这些药物是实验性的，文献并不能保证其安全性和疗效。在这些不确定的时期，本研究的结果强调了监测患者的重要性。
